Overview
Black Diamond Q2 net loss narrows to $10.6 mln from $19.9 mln yr/yr
Exploring partnerships to advance silevertinib development in NSCLC and GBM
Outlook
Black Diamond expects Q4 2025 data release for silevertinib Phase 2 trial
Company plans FDA meeting in 1H 2026 for silevertinib NSCLC path
Black Diamond exploring partnerships for silevertinib pivotal development
Company sees cash funding operations into Q4 2027
Result Drivers
EXPENSE REDUCTION - Reduced R&D and G&A expenses due to workforce efficiencies and restructuring
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income | -$10.56 mln | ||
Q2 Basic EPS | -$0.19 | ||
Q2 Cash & Investments | $142.80 mln | ||
Q2 Income From Operations | -$13.42 mln | ||
Q2 Operating Expenses | $13.42 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $11.00, about 75.5% above its August 6 closing price of $2.69
Press Release: ID:nGNX3VLXy8
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.